Individuals with CFRD and the G551D-CFTR mutation who are treated with ivacaftor often show an improvement in insulin secretion [53], a decrease in insulin use and occasionally a complete resolution of CFRD [54,55], once again illustrating that not all CF-related complications are irreversible. This evidence concerns the gene INS and cystic fibrosis.